Cutler Group’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-200
Closed -$6K 3171
2023
Q4
$6K Sell
200
-700
-78% -$20.1K ﹤0.01% 2667
2023
Q3
$28K Buy
900
+500
+125% +$19.4K ﹤0.01% 1810
2023
Q2
$16K Hold
400
﹤0.01% 1972
2023
Q1
$14K Sell
400
-100
-20% -$3.92K ﹤0.01% 2117
2022
Q4
$17K Sell
500
-6,000
-92% -$285K ﹤0.01% 2341
2022
Q3
$363K Buy
6,500
+1,500
+30% +$93.1K 0.02% 679
2022
Q2
$258K Buy
5,000
+306
+7% +$15.5K 0.02% 865
2022
Q1
$341K Buy
4,694
+4,494
+2,247% +$381K 0.02% 858
2021
Q4
$23K Sell
200
-140
-41% -$17.5K ﹤0.01% 3016
2021
Q3
$45K Sell
340
-8,860
-96% -$1.34M ﹤0.01% 2604
2021
Q2
$1.49M Buy
+9,200
New +$716K 0.07% 304
2018
Q3
Sell
-1,362
Closed -$37K 4503
2018
Q2
$37K Sell
1,362
-2,700
-66% -$65.4K ﹤0.01% 1800
2018
Q1
$85K Buy
4,062
+2,864
+239% +$70.4K 0.01% 1292
2017
Q4
$23K Sell
1,198
-3,278
-73% -$75.7K ﹤0.01% 2445
2017
Q3
$111K Buy
4,476
+2,355
+111% +$44.4K ﹤0.01% 1593
2017
Q2
$33K Buy
+2,121
New +$29.6K ﹤0.01% 2907

Other funds holding NTLA

Cutler Group's NTLA Position: Q1 2024 in Review

Cutler Group sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 200 shares — an estimated $6K sold.

Cutler Group first reported a position in NTLA in Q2 2017 and held it in 16 quarters. The position peaked at $1.49M in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Cutler Group reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 200 Intellia Therapeutics shares in Q1 2024, an estimated $6K.
  • Cutler Group first reported a position in Intellia Therapeutics in Q2 2017 and held it in 16 quarters.
  • Cutler Group's Intellia Therapeutics position peaked at $1.49M in Q2 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.